Inozyme Pharma’s (INZY) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Inozyme Pharma (NASDAQ:INZY) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $14.00 price target on the stock.

A number of other analysts have also weighed in on INZY. Bank of America lowered their price objective on shares of Inozyme Pharma from $16.00 to $14.00 and set a buy rating for the company in a research note on Tuesday, April 9th. Wells Fargo & Company initiated coverage on shares of Inozyme Pharma in a research report on Thursday, May 30th. They issued an overweight rating and a $14.00 price target for the company. Wedbush reissued an outperform rating and set a $15.00 price objective on shares of Inozyme Pharma in a report on Tuesday, May 7th. Finally, Needham & Company LLC restated a buy rating and set a $23.00 target price on shares of Inozyme Pharma in a report on Wednesday, May 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and an average price target of $16.00.

Inozyme Pharma Trading Up 0.2 %

Shares of INZY opened at $4.42 on Tuesday. Inozyme Pharma has a 1-year low of $2.69 and a 1-year high of $7.80. The company has a 50-day moving average of $4.60 and a 200 day moving average of $5.09. The firm has a market capitalization of $273.42 million, a price-to-earnings ratio of -3.23 and a beta of 1.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 14.05 and a quick ratio of 14.05.

Inozyme Pharma (NASDAQ:INZY) last issued its earnings results on Tuesday, May 7th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). On average, research analysts expect that Inozyme Pharma will post -1.59 EPS for the current year.

Hedge Funds Weigh In On Inozyme Pharma

A number of large investors have recently made changes to their positions in INZY. Values First Advisors Inc. purchased a new position in Inozyme Pharma during the 4th quarter worth $59,000. SG Americas Securities LLC boosted its holdings in Inozyme Pharma by 46.9% in the fourth quarter. SG Americas Securities LLC now owns 21,236 shares of the company’s stock worth $90,000 after acquiring an additional 6,784 shares in the last quarter. Superstring Capital Management LP purchased a new stake in shares of Inozyme Pharma during the fourth quarter worth about $528,000. Schonfeld Strategic Advisors LLC increased its holdings in shares of Inozyme Pharma by 346.8% during the third quarter. Schonfeld Strategic Advisors LLC now owns 311,880 shares of the company’s stock valued at $1,310,000 after acquiring an additional 242,080 shares in the last quarter. Finally, Laurion Capital Management LP raised its position in shares of Inozyme Pharma by 170.5% in the 3rd quarter. Laurion Capital Management LP now owns 677,329 shares of the company’s stock valued at $2,845,000 after purchasing an additional 426,961 shares during the last quarter. 88.30% of the stock is owned by institutional investors and hedge funds.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.